Vaccination against COVID-19 is in full swing around the world, especially in view of the prevalence of the new Omicron strain that has dramatically increased the number of new cases.
Vaccinated people may experience transient and mild reactions after vaccination and, less commonly, more serious side effects.
The Doctors of the Therapeutic Clinic of the Medical School of the National and Kapodistrian University of Athens Theodora Psaltopoulou, Giannis Danasis, Panos Malandrakis and Thanos Dimopoulos (Rector of EKPA) summarize the relevant publication of AL Beatty and associates in the journal JAMA Network Open (JAMA Netw Open. 2021; 4 (12): e2140364.).
The researchers evaluated the factors that may be associated with the occurrence of side effects after vaccination against COVID-19.
The study was performed between 26 May 2020 and 19 May 2021 and included those vaccinated with at least 1 dose of COVID-19 vaccine. A total of data from 19,586 people were included. The median age was 54 years (age range 38 to 66 years), while 68.8% (13,420 people) were women.
Allergic reaction or rash reported in 26 of 8,680 subjects (0.3%) after the first dose of BNT162b2 mRNA (Pfizer / BioNTech) or mRNA-1273 (Moderna) vaccine, in 27 of 11,141 subjects (0.2%) after two doses of BNT162b2 or mRNA-1273 or a single dose of JNJ-78436735 (Johnson & Johnson).
The main factors associated with the occurrence of side effects were the number of doses of the vaccine (more likely with more doses), the type of vaccine (more likely with mRNA-1273 compared to BNT162b2, and more likely with BNT162b2 compared to JNJ-78436735), age (more likely in younger people), sex (more likely in women), and previous COVID-19 disease before vaccination.
In conclusion, the specific study that collected data from daily clinical practice showed that Serious side effects of COVID-19 vaccines were rare.
The two doses of the vaccine, the type of vaccine, the youngest age, the female sex and the individual history of COVID-19 before vaccination were identified as risk factors that increased the risk of side effects.
Pharmacovigilance is important to continue throughout the course of the COVID-19 vaccine program, including booster doses.
Follow Skai.gr on Google News
and be the first to know all the news
.
